ATF2 (Ab-71 or 53) Antibody

What is ATF2 and what are its main biological functions?

ATF2 (Activating Transcription Factor 2) is a multifunctional transcriptional activator that regulates the transcription of various genes involved in anti-apoptosis, cell growth, and DNA damage response. Depending on its binding partner, ATF2 binds to either CRE (cAMP response element) consensus sequences (5'-TGACGTCA-3') or AP-1 (activator protein 1) consensus sequences (5'-TGACTCA-3') .

ATF2 exhibits dual localization and function:

• In the nucleus: Contributes to global transcription, DNA damage response, and specific transcriptional activities related to cell development, proliferation, and death

• In the cytoplasm: Interacts with and perturbs HK1- and VDAC1-containing complexes at the mitochondrial outer membrane, thereby impairing mitochondrial membrane potential, inducing mitochondrial leakage, and promoting cell death

Additionally, ATF2 exhibits histone acetyltransferase (HAT) activity, specifically acetylating histones H2B and H4 in vitro .

What is the significance of Thr71 and Thr53 phosphorylation in ATF2 function?

Phosphorylation of ATF2 at Thr71 (and the corresponding Thr53 in ATF7) plays a critical role in its activation. The phosphorylated form of ATF2 (mediated by ATM) has several important functions:

• It plays a role in the DNA damage response

• It is involved in the ionizing radiation (IR)-induced S phase checkpoint control

• It participates in the recruitment of the MRN complex into the IR-induced foci (IRIF)

Research has demonstrated that stress and growth factors activate ATF2 mainly via sequential phosphorylation of two conserved threonine residues (Thr69 and Thr71) in its activation domain. These phosphorylation events are essential for transcriptional activation, and mutations of these sites result in the loss of stress-induced transcription by ATF2 .

How do I choose between antibodies targeting single vs. dual phosphorylation sites of ATF2?

The choice between antibodies targeting single phosphorylation (e.g., only Thr71) versus dual phosphorylation (Thr69+Thr71) of ATF2 depends on your research questions:

Single phosphorylation antibodies (e.g., phospho-Thr71):

• Suitable for detecting early phosphorylation events in signaling cascades

• Useful when studying the two-step mechanism of ATF2 activation, as Thr71 mono-phosphorylation precedes Thr69+71 dual phosphorylation

• Essential for distinguishing between the Ras-Raf-MEK pathway (which primarily induces Thr71 mono-phosphorylation) and the RalGDS-Ral pathway (required for subsequent Thr69+71 dual phosphorylation)

Dual phosphorylation antibodies (e.g., phospho-Thr69+71):

• Appropriate for detecting fully activated ATF2

• More specific for transcriptional activation status as dual phosphorylation is required for maximal transcriptional activity

• Better for studies focused on downstream effects of ATF2 activation

Research findings indicate that in growth factor signaling, ATF2 activation follows a two-step mechanism: first, Thr71 mono-phosphorylation executed predominantly by the Ras-Raf-MEK pathway, and second, Thr69+71 dual phosphorylation via RalN28- and SB203580-inhibitable factors .

What validation methods should I use to confirm ATF2 antibody specificity?

To ensure the specificity and reliability of ATF2 (Ab-71 or 53) antibody, implement the following validation strategies:

1. Positive and negative controls:

• Use cell lines or tissues known to express high levels of ATF2 (e.g., HeLa, MCF-7, NIH-3T3)

• Include a negative control using non-specific antibodies (e.g., rabbit IgG)

• Compare results with ATF2 knockout or knockdown samples

2. Phosphorylation-specific validation:

• Use phosphatase treatment to demonstrate phosphorylation specificity

• Include samples treated with kinase inhibitors (e.g., U0126 for MEK inhibition, SB203580 for p38 inhibition) to validate pathway-specific phosphorylation

• For mono vs. dual phosphorylation specificity, compare results from antibodies specific for mono-phosphorylated ATF2 (Thr71) versus dual-phosphorylated ATF2 (Thr69+71)

3. Stimulation experiments:

• Treat cells with known ATF2 activators (e.g., anisomycin, UV irradiation, or growth factors like insulin or EGF)

• Use time-course experiments to track phosphorylation kinetics

4. Peptide competition:

• Perform immunohistochemistry with and without preincubation with a blocking peptide

Researchers have successfully validated ATF2 phosphorylation antibodies using these approaches. For example, in a study examining ATF2 activation by growth factors, researchers used western blot analysis with anti-phospho-Thr71-ATF2 (recognizing mono-phosphorylated ATF2) and anti-phospho-Thr69+71-ATF2 (recognizing dual-phosphorylated ATF2) antibodies to distinguish between different phosphorylation states .

What are the optimal conditions for using ATF2 (Ab-71 or 53) antibody in Western blotting?

For optimal Western blotting results with ATF2 (Ab-71 or 53) antibody, follow these methodological recommendations:

Sample preparation:

• For phosphorylation studies, rapidly lyse cells with phosphatase inhibitors to preserve phosphorylation status

• Process samples quickly and keep them cold to prevent dephosphorylation

Protocol parameters:

• Recommended dilutions: Generally 1:1000-1:2000, but may vary by manufacturer

• For phospho-ATF2 (Thr71)/ATF7 (Thr53) antibodies, dilutions of 1:2000-1:16000 have been validated

• Expected molecular weight: ATF2 is typically observed at 65-75 kDa, though the theoretical mass is lower (55 kDa)

Detection systems:

• Use enhanced chemiluminescence (ECL) for high sensitivity

• For phosphorylation-specific detection, consider using fluorescent secondary antibodies for multiplex detection of total and phosphorylated ATF2

Controls and validation:

• Include positive control lysates (e.g., anisomycin-treated NIH/3T3 cells for phospho-ATF2)

• For pathway analysis, include samples treated with specific pathway inhibitors (e.g., U0126 for MEK inhibition)

Troubleshooting:

• If background is high, increase blocking time or use alternative blocking agents

• For weak signals, extend antibody incubation time or increase concentration

• Consider using PVDF membranes for better protein retention and higher signal

Western blotting experiments have shown that growth factors like insulin induce strong phosphorylation of ATF2 at Thr69 and Thr71 within 5 minutes after addition, while phorbol esters like TPA induce only Thr71 mono-phosphorylation .

How can I optimize ChIP protocols when using ATF2 (Ab-71 or 53) antibody?

For effective Chromatin Immunoprecipitation (ChIP) using ATF2 (Ab-71 or 53) antibodies, implement these methodological optimizations:

Crosslinking and chromatin preparation:

• Use 1% formaldehyde for 8-10 minutes at room temperature for optimal DNA-protein crosslinking

• Stop crosslinking with glycine (0.125M final concentration)

• Sonicate chromatin to obtain DNA fragments averaging 400 bp in length

• Verify sonication efficiency by running a small aliquot on an agarose gel

Immunoprecipitation:

• Use 5-10 μg of antibody per ChIP reaction for 1×10^6 cells

• Include a non-specific antibody control (e.g., rabbit anti-chicken IgG)

• Precipitate antibody-bound complexes with protein A/G sepharose beads

Washing and elution:

• Perform stringent washes to reduce non-specific binding

• Reverse crosslinks at 65°C overnight

• Purify DNA using phenol-chloroform extraction or commercial kits

Analysis and quantification:

• Analyze precipitated DNA by qPCR, focusing on known ATF2 binding regions

• For phosphorylation-specific ChIP, consider using antibodies that specifically recognize ATF2 phosphorylated on threonine 71

Special considerations for phospho-ATF2:

• For temporal studies, perform a time course analysis to correlate ATF2 phosphorylation with histone modifications and gene expression

• Research has shown that phosphorylation of ATF2 bound to the CHOP AARE (amino acid response element) precedes histone acetylation, suggesting a role in chromatin structure modification

Studies have demonstrated that ATF2 bound to regulatory elements plays a crucial role in vivo in the acetylation of histones H4 and H2B in response to environmental stressors such as amino acid starvation, which may be involved in modifying chromatin structure to enhance transcription of amino acid-regulated genes .

What optimization strategies should I employ for using ATF2 (Ab-71 or 53) antibody in immunohistochemistry?

For optimal immunohistochemistry (IHC) results with ATF2 (Ab-71 or 53) antibody, consider these protocol recommendations:

Sample preparation:

• For paraffin-embedded tissues, perform heat-mediated antigen retrieval with citrate buffer (pH 6.0)

• For phosphorylation-specific detection, use freshly fixed tissues to preserve phosphorylation status

• Consider using controlled fixation times to prevent overfixation

Protocol parameters:

• Recommended dilutions: Generally 1:50-1:100 for IHC-P applications

• Include blocking steps to minimize non-specific binding

• Optimize incubation temperature and duration for primary antibody (typically overnight at 4°C or 1-2 hours at room temperature)

Detection and visualization:

• Use sensitive detection systems such as polymer-based detection kits

• For phospho-specific staining, consider using amplification methods like tyramide signal amplification

• Include counterstaining with hematoxylin for better visualization of tissue morphology

Controls and validation:

• Include positive control tissues (e.g., human breast carcinoma tissue for phospho-ATF2)

• Perform peptide competition assays to confirm antibody specificity

• Include appropriate negative controls (primary antibody omission, isotype controls)

Special considerations for phospho-ATF2:

• Rapid fixation is crucial to preserve phosphorylation status

• Consider using phosphatase inhibitors during tissue processing

• Compare staining patterns with total ATF2 antibodies to assess phosphorylation dynamics

Research has demonstrated successful immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using ATF2 (Phospho-Thr71 or 53) Antibody, with specific staining eliminated when using the same antibody preincubated with a blocking peptide .

How does the phosphorylation status of ATF2 at Thr71/53 correlate with different cellular stress responses?

The phosphorylation of ATF2 at Thr71 (and the corresponding Thr53 in ATF7) serves as a molecular switch in response to different cellular stressors, with distinct kinetics and outcomes:

Growth factor-induced phosphorylation:

• Growth factors like insulin and EGF induce ATF2 Thr71 and Thr69+71 phosphorylation through a two-step mechanism:

  • Initial Thr71 mono-phosphorylation via the Ras-Raf-MEK pathway

  • Subsequent Thr69+71 dual phosphorylation via the RalGDS-Ral pathway

• This sequential phosphorylation is rapid, occurring within 5 minutes of stimulation

Stress-induced phosphorylation:

• Stressors like UV irradiation, inflammatory cytokines, and genotoxic agents activate p38 MAPK and JNK pathways

• These stress-activated kinases can directly phosphorylate both Thr69 and Thr71 sites simultaneously

• Unlike growth factor stimulation, stress-induced phosphorylation is not inhibited by dominant-negative Ras mutants

Temporal dynamics:

• In amino acid starvation responses, ATF2 Thr71 phosphorylation precedes histone acetylation, ATF4 binding, and the increase in stress-responsive gene expression

• Phosphorylation can be detected as early as 30 minutes after stress induction, reaching maximum levels within 2 hours

Pathway selectivity:

Understanding these distinct phosphorylation patterns is crucial for interpreting experimental results and designing appropriate controls when studying ATF2-mediated responses to different cellular stressors .

What are the key methodological considerations when investigating the interaction between ATF2 phosphorylation and chromatin modifications?

Investigating the relationship between ATF2 phosphorylation and chromatin modifications requires careful methodological planning:

Sequential ChIP (Re-ChIP) approach:

• First immunoprecipitate with phospho-ATF2 antibodies, then re-immunoprecipitate with antibodies against histone modifications

• This approach can establish direct links between ATF2 phosphorylation status and specific histone modifications at target genes

• Critical control: Use non-specific IgG in the first immunoprecipitation step

Temporal analysis coordination:

• Design time-course experiments to track the sequence of events

• Research has shown that ATF2 Thr71 phosphorylation precedes histone H4 and H2B acetylation during amino acid starvation responses

• Collect samples at multiple time points (0, 30min, 1h, 2h, 4h) to capture the full sequence of events

Integrative analysis:

• Combine ChIP for phospho-ATF2 and histone modifications with expression analysis of target genes

• Correlate changes in ATF2 phosphorylation, histone modifications, and gene expression levels

• Consider using ChIP-seq for genome-wide analysis of these relationships

Inhibitor studies:

• Use specific kinase inhibitors (JNK inhibitors, p38 inhibitors) to block ATF2 phosphorylation

• Monitor effects on histone modifications and gene expression

• Example experimental design:

  • Pretreat cells with inhibitors (JNK-IN-8, SB203580)

  • Apply stress stimulus

  • Perform ChIP for ATF2 and histone modifications

  • Analyze target gene expression

Key technical considerations:

• Rapid sample processing to preserve phosphorylation status

• Use of phosphatase inhibitors in all buffers

• Careful optimization of sonication conditions to ensure efficient chromatin fragmentation

• Validation of antibody specificity for both phospho-ATF2 and histone modification antibodies

Research has demonstrated that ATF2 bound to the CHOP AARE plays a crucial role in vivo in the acetylation of histones H4 and H2B in response to amino acid starvation, suggesting that phosphorylated ATF2 may be involved in modifying chromatin structure to enhance transcription of stress-responsive genes .

How do JNK and p38 MAPK differentially regulate ATF2 phosphorylation at Thr71/53, and what are the experimental approaches to distinguish their contributions?

JNK and p38 MAPK regulate ATF2 phosphorylation through distinct mechanisms that can be experimentally differentiated:

Structural basis of differential regulation:

Differential phosphorylation patterns:

• JNK-mediated phosphorylation remains unaffected when the p38-specific binding region (92-FENEF-96) is mutated to (92-AENEA-96)

• p38-mediated phosphorylation is greatly reduced by this mutation

• JNK binding to ATF2 is similar whether JNK is activated or not

• p38 binding to ATF2 is elevated when p38 is activated

Experimental approaches to distinguish their contributions:

• Selective inhibitors:

  • Use JNK-specific inhibitors (e.g., JNK-IN-8) and p38-specific inhibitors (e.g., SB203580)

  • Monitor effects on ATF2 phosphorylation under different stress conditions

  • Example finding: JNK activation decreases binding of ATF2 TAD to pp-p38, as cells treated with JNK-specific inhibitor display elevated pp-p38:WT TAD binding

• Mutational analysis:

  • Create ATF2 mutants with altered JNK or p38 binding sites

  • Compare phosphorylation patterns in response to different stimuli

  • For example, ATF2 S90N mutant shows increased binding to pp-p38 over wild-type ATF2

• Pathway-specific activators:

  • Use anisomycin for simultaneous JNK and p38 activation

  • Use TPA for specific MEK-ERK pathway activation without activating JNK/p38

  • Example experimental design:

    Treatment	Pathway Activated	Expected Phosphorylation
    Anisomycin	JNK + p38	Thr69+71 dual phosphorylation
    TPA	Raf-MEK-ERK	Thr71 mono-phosphorylation only
    UV	JNK > p38	Thr69+71 dual phosphorylation
    Osmotic stress	p38 > JNK	Thr69+71 dual phosphorylation

• In vitro kinase assays:

  • Use purified kinases and ATF2 substrates

  • Include ATF2 variants with Thr69 and/or Thr71 replaced by alanines

  • Analyze both radioactive phosphate incorporation and antibody reactivity

Research using these approaches has demonstrated that growth factors activate ATF2 via a two-step mechanism, with ERK primarily phosphorylating Thr71, while stress-induced phosphorylation of both Thr69 and Thr71 is mediated by p38 and JNK .

What are the critical considerations when interpreting contradictory results from different phospho-ATF2 antibodies in multi-omics studies?

When faced with contradictory results from different phospho-ATF2 antibodies in multi-omics studies, consider these critical interpretative frameworks:

Epitope specificity differences:

• Phospho-Thr71-ATF2 antibodies recognize ATF2 mono-phosphorylated at Thr71 only

• Phospho-Thr69+71-ATF2 antibodies recognize dual-phosphorylated ATF2 but not mono-phosphorylated ATF2

• These distinct specificities may yield apparently contradictory results that actually reflect different activation states

Temporal dynamics considerations:

• ATF2 phosphorylation follows specific temporal patterns depending on stimulus

• Growth factor stimulation induces sequential phosphorylation (Thr71 → Thr69+71)

• Stress stimulation may induce simultaneous phosphorylation of both sites

• Sampling at different time points may capture different phases of this dynamic process

Pathway-specific activation patterns:

• The Raf-MEK pathway predominantly induces Thr71 mono-phosphorylation

• The RalGDS-Ral pathway and stress-activated kinases (p38/JNK) induce Thr69+71 dual phosphorylation

• Different experimental conditions may activate these pathways to varying degrees

Antibody validation framework:

• Cross-validation approach:

  • Use multiple antibodies targeting different phosphorylation states

  • Correlate results with functional readouts (e.g., transcriptional activity)

  • Implement pathway-specific inhibitors to confirm specificity

• Integration strategy for contradictory data:

  • Map observations to known signaling pathways and temporal patterns

  • Consider using computational modeling to reconcile apparently conflicting results

  • Triangulate findings with orthogonal methods (mass spectrometry, kinase assays)

• Multi-omics data integration:

  • Correlate phospho-ATF2 antibody signals with transcriptomic changes in ATF2 target genes

  • Integrate phosphoproteomic data to map the activation status of upstream kinases

  • Use epigenomic data (ChIP-seq) to correlate phospho-ATF2 binding with chromatin modifications

Research has demonstrated that apparently contradictory results can be reconciled by understanding the complex regulation of ATF2. For example, in a study examining ATF2 activation by growth factors, researchers found that TPA treatment did not induce detectable ATF2 Thr69+71 phosphorylation but did induce strong Thr71 mono-phosphorylation, which was completely prevented by MEK inhibition. This initially contradictory finding was explained by the two-step activation mechanism .

What are common troubleshooting strategies for inconsistent phospho-ATF2 (Thr71/53) antibody signals in Western blotting?

When encountering inconsistent phospho-ATF2 (Thr71/53) antibody signals in Western blotting, implement these troubleshooting strategies:

Sample preparation issues:

• Phosphorylation preservation:

  • Rapidly harvest cells and immediately lyse in buffer containing phosphatase inhibitors

  • Keep samples cold throughout processing

  • Consider using phosphatase inhibitor cocktails containing sodium fluoride, sodium orthovanadate, and β-glycerophosphate

• Protein degradation:

  • Add protease inhibitors to lysis buffer

  • Process samples quickly and keep cold

  • Avoid repeated freeze-thaw cycles

Technical optimization:

• Antibody dilution optimization:

  • Titrate antibody concentrations (typically 1:1000-1:2000, but may require 1:500-1:16000 depending on the antibody)

  • Test multiple incubation times and temperatures

• Detection system improvements:

  • For weak signals, try more sensitive ECL substrates

  • Consider using fluorescent secondary antibodies for improved quantification

  • For high background, increase blocking time or try alternative blocking agents

Cell signaling considerations:

• Kinetics and timing:

  • ATF2 phosphorylation is dynamic and peaks at specific times post-stimulation

  • For growth factors, phosphorylation can peak within 5-15 minutes

  • For stress responses, optimal time points may be 30-120 minutes

• Pathway crosstalk:

  • Pre-treatment with certain inhibitors can paradoxically enhance other pathways

  • For example, MEK inhibition with U0126 can slightly potentiate insulin-induced JNK and p38 activity

  • Consider using multiple specific inhibitors to parse pathway contributions

Antibody-specific considerations:

• Mono vs. dual phosphorylation:

  • If using mono-phospho antibodies (e.g., pThr71), signal may vary based on dual phosphorylation status

  • If using dual-phospho antibodies (e.g., pThr69+71), no signal will be detected for mono-phosphorylated ATF2

  • Consider using both types of antibodies in parallel

• Epitope masking:

  • Certain binding partners or conformational changes may mask antibody epitopes

  • Try alternative sample preparation methods (e.g., different detergents, denaturing conditions)

Research has shown that the observed molecular weight of ATF2 (65-75 kDa) is larger than the theoretical value, which may be related to post-translational modifications . This discrepancy should be considered when interpreting Western blot results.

How can I optimize protocols for studying the kinetics of ATF2 phosphorylation at Thr71/53 in response to cellular stress?

To effectively study the kinetics of ATF2 phosphorylation at Thr71/53 in response to cellular stress, implement these optimized protocols:

Time-course design optimization:

• High-resolution early timepoints:

  • Include very early time points (0, 2, 5, 10, 15, 30 min) to capture initial phosphorylation events

  • Research shows that growth factors can induce phosphorylation within 5 minutes

• Extended time coverage:

  • Include later time points (1, 2, 4, 8 hrs) to track persistence and decline of phosphorylation

  • For amino acid starvation responses, ATF2 phosphorylation peaks at approximately 2 hours

Stimulation protocols:

• Growth factor stimulation:

  • Serum-starve cells for 12-24 hours before stimulation

  • Use defined concentrations of growth factors (e.g., insulin, EGF)

  • For insulin, use cell lines like A14 or 3T3L1 adipocytes for robust responses

• Stress induction protocols:

  • For osmotic stress, use 0.4M sorbitol

  • For DNA damage, use methyl methanesulfonate (MMS)

  • For amino acid starvation, transfer cells to media lacking specific amino acids (e.g., leucine)

Sample processing for phosphorylation preservation:

• Rapid termination:

  • Use direct lysis in 1X SDS sample buffer pre-heated to 95°C for immediate denaturation

  • Alternatively, rapidly rinse cells with ice-cold PBS containing phosphatase inhibitors

• Phosphatase inhibitor optimization:

  • Include multiple phosphatase inhibitor types (serine/threonine and tyrosine phosphatase inhibitors)

  • Use freshly prepared inhibitor cocktails

Multi-readout analytical approaches:

• Parallel antibody analysis:

  • Use antibodies specific for mono-phosphorylated ATF2 (Thr71) and dual-phosphorylated ATF2 (Thr69+71)

  • Include total ATF2 antibody to normalize for expression levels

• Pathway activation markers:

  • Simultaneously monitor upstream kinase activation (phospho-JNK, phospho-p38, phospho-ERK)

  • Include downstream targets to confirm functional consequences of ATF2 phosphorylation

Kinetic data analysis:

• Calculate the t½ for phosphorylation and dephosphorylation

• Consider using computational modeling to integrate pathway dynamics

• Compare kinetics across different stressors and in different cell types

Research using these approaches has revealed important insights into ATF2 phosphorylation kinetics. For example, researchers have shown that in amino acid starvation, ATF2 phosphorylation on Thr71 was detectable 30 min after removal of leucine from the medium and reached maximum levels within 2 hours, preceding histone acetylation and gene expression changes .

What advanced techniques can be used to simultaneously analyze ATF2 phosphorylation states and their impact on gene transcription?

To comprehensively analyze the relationship between ATF2 phosphorylation states and their transcriptional consequences, employ these advanced integrated techniques:

1. Phosphorylation-specific Chromatin Immunoprecipitation (ChIP) approaches:

• Sequential ChIP (Re-ChIP):

  • First immunoprecipitate with phospho-ATF2 antibodies, then re-immunoprecipitate with antibodies against histone modifications

  • This establishes direct links between ATF2 phosphorylation status and specific histone modifications

• ChIP-seq with phospho-specific antibodies:

  • Perform genome-wide mapping of phospho-ATF2 binding sites

  • Compare binding profiles using antibodies recognizing different phosphorylation states (mono vs. dual phosphorylation)

  • Example application: ATF2 antibody [E243] has been validated for ChIP and ChIC/CUT&RUN-seq applications

2. Integrated multi-omics approaches:

• Phospho-ChIP-seq with RNA-seq:

  • Correlate phospho-ATF2 binding with global transcriptional changes

  • Identify direct transcriptional targets of differentially phosphorylated ATF2

  • Example workflow:

    • Perform ChIP-seq with phospho-ATF2 (Thr71) and phospho-ATF2 (Thr69+71) antibodies

    • In parallel, perform RNA-seq on the same samples

    • Integrate datasets to identify genes with phospho-ATF2 binding that show expression changes

• ChIP-seq with histone modification mapping:

  • Perform parallel ChIP-seq for phospho-ATF2 and key histone modifications (H3K27ac, H3K4me3)

  • Analyze correlation between phospho-ATF2 binding and active chromatin marks

  • Research has shown that ATF2 bound to regulatory elements plays a crucial role in the acetylation of histones H4 and H2B

3. Advanced cellular and molecular techniques:

• Phospho-specific Proximity Ligation Assay (PLA):

  • Visualize interactions between phospho-ATF2 and transcriptional machinery components in situ

  • Detect associations with different cofactors based on phosphorylation status

• CRISPR/Cas9 gene editing of phosphorylation sites:

  • Generate cell lines with ATF2 T71A and/or T69A/T71A mutations

  • Compare transcriptional responses to different stimuli

  • Perform ChIP-seq in these mutant lines to assess impact on genomic binding and histone modifications

4. Real-time monitoring approaches:

• Live-cell imaging with phospho-sensors:

  • Develop FRET-based sensors for ATF2 phosphorylation

  • Monitor phosphorylation kinetics in real-time in living cells

  • Correlate with transcriptional reporters for ATF2 target genes

• Nascent RNA sequencing (NET-seq, GRO-seq):

  • Measure immediate transcriptional responses downstream of ATF2 phosphorylation

  • Correlate with phosphorylation kinetics to establish direct causal relationships

Studies have demonstrated that phosphorylation of ATF2 bound on the CHOP AARE precedes histones H4 and H2B acetylation and CHOP mRNA increase, suggesting a temporal sequence of events where ATF2 phosphorylation leads to chromatin modification and subsequently to increased gene expression .